{"symbol":"LLY","provider":"yahoo-finance","fetchedAt":"2025-12-26T04:28:52.714Z","asOfDate":"2025-12-25","articles":[{"id":"abdf303f-3943-3bca-bb90-a84a0130e56a","title":"Is Eli Lilly Pulling Ahead in the Weight Loss Drug Battle?","url":"https://finance.yahoo.com/m/abdf303f-3943-3bca-bb90-a84a0130e56a/is-eli-lilly-pulling-ahead-in.html","publisher":"Motley Fool","publishedAt":"2025-12-25T17:05:00.000Z","relatedTickers":["NVO"],"mainIdea":"Is Eli Lilly Pulling Ahead in the Weight Loss Drug Battle?","summary":"Motley Fool: Is Eli Lilly Pulling Ahead in the Weight Loss Drug Battle?. It's a two-horse race right now, sort of. Related tickers mentioned: NVO."},{"id":"c87560a2-11e3-316c-8db1-ebe5d2aba160","title":"As the FDA Approves a Wegovy Pill, Should You Buy, Sell, or Hold Novo Nordisk Stock?","url":"https://finance.yahoo.com/m/c87560a2-11e3-316c-8db1-ebe5d2aba160/as-the-fda-approves-a-wegovy.html","publisher":"Barchart","publishedAt":"2025-12-25T14:00:02.000Z","relatedTickers":["NVO","PFE"],"mainIdea":"As the FDA Approves a Wegovy Pill, Should You Buy, Sell, or Hold Novo Nordisk Stock?","summary":"Barchart: As the FDA Approves a Wegovy Pill, Should You Buy, Sell, or Hold Novo Nordisk Stock?. As Novo Nordisk’s FDA-approved Wegovy pill sets up a high-stakes comeback, should NVO be back on investors’ radar now? Related tickers mentioned: NVO, PFE."},{"id":"59c8c41f-e1b0-34d1-a798-938ede3a1661","title":"Novo, Lilly race to cement lead in India’s obesity drug market, Reuters says","url":"https://finance.yahoo.com/news/novo-lilly-race-cement-lead-114028860.html","publisher":"TipRanks","publishedAt":"2025-12-25T11:40:28.000Z","relatedTickers":["NONOF","NVO"],"mainIdea":"Novo, Lilly race to cement lead in India’s obesity drug market, Reuters says","summary":"TipRanks: Novo, Lilly race to cement lead in India’s obesity drug market, Reuters says. Eli Lilly (LLY) and Novo Nordisk (NVO) are racing to cement their lead in India’s obesity drug market before cheaper generic version enter stores in March, Rishika Sadam of Reuters reports. Novo’s strategy focuses on price cuts and accelerated launches while Lilly’s products benefitted from entering the market early. Both companies have outreached to doctors, advertised heavily, provided incentives to patients, and entered distribution deals with local drugmakers, doctors, analysis, and others i Related tickers mentioned: NONOF, NVO."},{"id":"275dceb5-bed9-33b6-b0c8-8ed3f7c655a6","title":"Caliway's Fat Reduction Drug Candidate CBL-514 Completes U.S. FDA IND Submission for Phase 2 Clinical Study in Weight Management, Expanding Development Combined with GLP-1RA-Based Weight-Loss Therapies","url":"https://finance.yahoo.com/news/caliways-fat-reduction-drug-candidate-020500815.html","publisher":"PR Newswire","publishedAt":"2025-12-25T02:05:00.000Z","relatedTickers":[],"mainIdea":"Caliway's Fat Reduction Drug Candidate CBL-514 Completes U.S. FDA IND Submission for Phase 2 Clinical Study in Weight Management, Expanding Development Combined with GLP-1RA-Based Weight-Loss Therapies","summary":"PR Newswire: Caliway's Fat Reduction Drug Candidate CBL-514 Completes U.S. FDA IND Submission for Phase 2 Clinical Study in Weight Management, Expanding Development Combined with GLP-1RA-Based Weight-Loss Therapies. Caliway Biopharmaceuticals (TWSE: 6919) today announced that it has completed the submission of an Investigational New Drug (IND) application to the U.S. FDA for a Phase 2 clinical study of its world's first large-area localized fat reduction drug candidate, CBL-514, for the weight management indication. This submission accelerates the clinical development of CBL-514 in combination with GLP-1R agonist (GLP-1RA) therapies and expands the Company's R&D footprint in the global weight management fie"},{"id":"d646d17f-65d4-3c5b-943a-6814d905b8c6","title":"Weight-loss pill approval spurs food industry overhaul","url":"https://finance.yahoo.com/video/weight-loss-pill-approval-spurs-224626785.html","publisher":"Reuters Videos","publishedAt":"2025-12-24T22:46:26.000Z","relatedTickers":["CAG","NSRGF","NVO"],"mainIdea":"Weight-loss pill approval spurs food industry overhaul","summary":"Reuters Videos: Weight-loss pill approval spurs food industry overhaul. Related tickers mentioned: CAG, NSRGF, NVO."},{"id":"727ca8e3-ac25-33d3-8de8-b180eb99424d","title":"Got $1,000? 2 High-Yield Healthcare Stocks to Buy and Hold Forever","url":"https://finance.yahoo.com/m/727ca8e3-ac25-33d3-8de8-b180eb99424d/got-%241%2C000%3F-2-high-yield.html","publisher":"Motley Fool","publishedAt":"2025-12-24T22:46:00.000Z","relatedTickers":["BMY","MDT","PFE"],"mainIdea":"Got $1,000? 2 High-Yield Healthcare Stocks to Buy and Hold Forever","summary":"Motley Fool: Got $1,000? 2 High-Yield Healthcare Stocks to Buy and Hold Forever. If you are looking for high yields, this drug maker and this device maker are both worth a deep dive today. Related tickers mentioned: BMY, MDT, PFE."}]}
